Mirum Pharmaceuticals, Inc. cash flow to debt ratio of 17.48% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Mirum Pharmaceuticals, Inc.'s free cash flow has increased 488.01% from $9.33M last year to $54.87M, signaling increasing performance

Mirum Pharmaceuticals, Inc.'s debt to equity ratio is 1.34, which means that the company's assets are unhealthy financed, signaling financial risk. READ MORE: A ratio over 0.60 means the company finances its assets with debt, signaling financial risk. If ratio is negative, the company spent its own equity and risks bankruptcy

Mirum Pharmaceuticals, Inc.'s debt has decreased relative to shareholder equity from 1.41 last year to 1.34 today, signaling strengthened financials

Mirum Pharmaceuticals, Inc. has a net debt to EBITDA ratio of 1.32x, which is below the 3.00x threshold, indicating healthy leverage and financial stability

Mirum Pharmaceuticals, Inc.'s interest coverage ratio is -4.87, which means that the company struggles to meet interest obligations, signaling financial risk.

Mirum Pharmaceuticals, Inc.'s profit margin has decreased (437.25%) in the last year from -26.10% to -140.24%, signaling decreasing performance

Mirum Pharmaceuticals, Inc.'s short-term assets of $549.68M exceed its short-term liabilities of $205.80M

Mirum Pharmaceuticals, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Mirum Pharmaceuticals, Inc.'s return on equity of -289.33%, is lower than 15.00%, indicating bad performance

Mirum Pharmaceuticals, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Mirum Pharmaceuticals, Inc. had positive net income in only 0.00 out of 5 years, indicating unstable earnings

Mirum Pharmaceuticals, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

Mirum Pharmaceuticals, Inc. has a free cash flow yield of 0.88%, which is below the 2.00% threshold, indicating limited cash return relative to market value

Mirum Pharmaceuticals, Inc.'s yearly earnings has increased -73.43% since last year from $-87.94M to $-23.36M, signaling increasing performance

Mirum Pharmaceuticals, Inc.'s yearly revenue has increased 54.74% since last year from $336.89M to $521.31M, signaling increasing performance

ROIC -11.30% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Mirum Pharmaceuticals, Inc.'s 3-year revenue CAGR of 89.13% is positive, indicating growing revenue over the past 3 years

Mirum Pharmaceuticals, Inc. had revenue growth in 5.00 out of 5 years, indicating consistent revenue performance

Mirum Pharmaceuticals, Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

Mirum Pharmaceuticals, Inc. has insufficient data to evaluate this check.

Mirum Pharmaceuticals, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Mirum Pharmaceuticals, Inc. is overvalued relative to its fair value price of 1.95 based on EBITDA multiple model

Mirum Pharmaceuticals, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Mirum Pharmaceuticals, Inc. has insufficient data to evaluate this check.

Mirum Pharmaceuticals, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Mirum Pharmaceuticals, Inc. has a price-to-book ratio of 30.04x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Mirum Pharmaceuticals, Inc. has a price-to-sales ratio of 10.91x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue